Olema Pharmaceuticals, Inc. 8-K

What Happened
Olema Pharmaceuticals, Inc. announced and filed an 8‑K on May 12, 2026 reporting its financial results for the quarter ended March 31, 2026. The company furnished a press release dated May 12, 2026 that summarizes the quarterly results. The filing was signed by Sean Bohen, M.D., Ph.D., President and Chief Executive Officer.

Key Details

• Filing date: May 12, 2026 (Form 8‑K).
• Reporting item: Item 2.02 — Results of Operations and Financial Condition (quarter ended March 31, 2026).
• Exhibit included: 99.1 — Press Release dated May 12, 2026; Exhibit 104 — Cover Page Interactive Data File (Inline XBRL).
• Authorized signature: /s/ Sean Bohen, M.D., Ph.D., President and CEO.

Why It Matters
This 8‑K notifies investors that Olema has publicly disclosed its latest quarterly financial results and made the full press release available as an exhibit. Retail investors should read the attached press release and any accompanying financial statements or XBRL data to see revenue, net income/loss, cash position, and management commentary for Q1 2026 — these details are required to assess near‑term performance and outlook. The filing does not disclose other material corporate actions (e.g., executive changes, mergers) beyond the financial results announcement.